Open AccessSuccessful nilotinib therapy in a CML affected patient with A380T, P407S and V468A mutations, and a previous suboptimal cytogenetic response to imatinib
Author(s) -
Fabio Stagno,
Alessandra Cupri,
Stefania Stella,
Michele Massimino,
Silvia Rita Vitale,
Paolo Vigneri
Publication year - 2015
Publication title -
clinical management issues
Language(s) - English
Resource type - Journals
eISSN - 2283-3137
pISSN - 1973-4832
DOI - 10.7175/cmi.v4i6s.1097
Subject(s) - medicine , nilotinib , imatinib , imatinib mesylate , myeloid leukemia , tyrosine kinase inhibitor , oncology , tyrosine kinase , cancer , receptor
Imatinib mesylate (IM) has shown unprecedented effectiveness in the treatment of Chronic Myeloid Leukemia (CML) patients (pts) in the chronic phase of the disease. However, some pts fail to respond or lose their initial response to IM. The European LeukemiaNet (ELN) published recommendations designed to identify patients responding poorly to imatinib. Here we report a case of a suboptimal cytogenetic responder to IM who had a successful response to the second generation tyrosine kinase inhibitor nilotinib (NIL). According to the ELN criteria, CML pts on IM-therapy might show a suboptimal response either because of failure to achieve a CCyR by 12 months of therapy or because of lack of a MMR after 18 months. The prognostic value of these two types of responders might be very different.